Claims for Patent: 5,491,130

Summary for Patent: 5,491,130

Title:	Peptide inhibitors of fibronectin and related collagen-binding proteins
Abstract:	Peptides derived from the second type 1 repeat of human endothelial cell thrombospondin which bind to the gelatin-binding domain of fibronectin have been isolated and synthetically produced. The peptides can be used to bind to fibronectin or other related collagen-binding proteins to inhibit fibronectin-dependent cell adhesion to collagen matrices and to inhibit interactions with collagen of other proteins that share homologies with the gelatin-binding domain of fibronectin.
Inventor(s):	Roberts; David D. (Bethesda, MD), Krutzsch; Henry C. (Bethesda, MD), Sipes; John M. (Cabin John, MD), Guo; Neng-hua (Gaithersburg, MD), Negre; Eric (Bethesda, MD)
Assignee:	The United States of America as represented by the Department of Health (Washington, DC)
Application Number:	07/973,235
Patent Claims:	1. A method for binding fibronectin comprising contacting fibronectin with an effective amount of a composition comprising a peptide having a specific binding affinity for the gelatin-binding domain of fibronectin, said peptide having from 3 to 18 amino acids in length and consisting of the sequence (A), wherein Xa is H or an amino acid sequence of from 1 to 13 amino acids derived from the consecutively occurring thrombospondin amino acid residues 394-420, Xb is serine, alanins, tryptophan, or threonine and Xc is OH, NH.sub.2, or an amino acid sequence of from I to 13 amino acids derived from the consecutively occurring human thrombospondin amino acid residues 424-450, and at least one of Xa and Xb includes a tryptophan residue located within three amino acid residues from Trp in sequence (A). 2. A method according to claim 1 wherein said method is conducted in vitro or in vivo. 3. A method according to claim 1 wherein said method is conducted in vitro. 4. A method according to claim 1 wherein said method is conducted in vivo. 5. A method according to claim 4 wherein said method is conducted in a patient. 6. A method for binding fibronectin, according to claim 5, wherein said peptide is a peptide having a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8. 7. A method for inhibiting enzymatic activity of collagenase in a patient in need of such treatment, which comprises administering to said patient an effective amount of at least one peptide contained in a pharmaceutically acceptable excipient or carrier, wherein said peptide is a peptide having a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8. 8. A method according to claim 5 wherein Xb is selected from the group consisting of serine, alanine and tryptophan. 9. The method according to claim 7 wherein said collagenase is endothelial collagenase. 10. A method according to claim 6 wherein said peptide is a peptide having SEQ ID No:1. 11. A peptide composition having a specific binding affinity for fibronectin, consisting essentially of a peptide selected from the group consisting of peptides having SEQ ID NO:1, SEQ ID NO:12 and SEQ ID NO:13. 12. A method according to claim 10, wherein said peptide further comprises an amino-terminal N-acetyl and carboxyl terminal amide.

Details for Patent 5,491,130

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-03-29